MARKET

GEMP

GEMP

Gemphire
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3601
+0.0091
+2.59%
Closed 16:00 11/12 EST
OPEN
0.3600
PREV CLOSE
0.3510
HIGH
0.3679
LOW
0.3500
VOLUME
46.01K
TURNOVER
--
52 WEEK HIGH
1.490
52 WEEK LOW
0.2840
MARKET CAP
5.36M
P/E (TTM)
-0.3122
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GEMP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GEMP News

  • Gemphire Shares Up 21.9%; Traders Circulate Oct. 22-Dated USPTO Abstract 'Treatment of NASH with Gemcabene'
  • Benzinga.10/22 14:19
  • The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
  • Benzinga.10/11 12:14
  • Stocks That Hit 52-Week Lows On Thursday
  • Benzinga.10/10 15:08
  • The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration
  • Benzinga.10/08 11:11

More

Industry

Biotechnology & Medical Research
+0.45%
Pharmaceuticals & Medical Research
+0.31%

Hot Stocks

Name
Price
%Change

About GEMP

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.
More

Webull offers Gemphire Therapeutics Inc (GEMP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.